Science Research Wellness: SRW
SRW Skl1 Mobility Joint Health Supplement for Comfort Flexibility and Active Living
SRW Skl1 Mobility Joint Health Supplement for Comfort Flexibility and Active Living
无法加载取货服务可用情况
Product Overview
Skl1 Mobility is positioned within the SRW “Cellular Aging” longevity range as targeted nutritional support for the skeletal system. The formulation combines three patented or trademark-standardised actives at clinically referenced doses: NEM® (a partially hydrolysed eggshell membrane standardised by ESM Technologies, USA), 5-LOXIN® (a Boswellia serrata gum-resin extract standardised to ≥30% AKBA, manufactured by PLT Health Solutions), and Palmitoylethanolamide (an ultramicronised endogenous N-acylethanolamine). Each component is supplied in a vegetarian capsule shell (HPMC) and is free of gluten, dairy, soy, and added sugar.
The product is designed as a daily oral supplement for adults experiencing intermittent joint stiffness, reduced range of motion, or load-induced joint discomfort. It is not a registered therapeutic medicine, does not treat osteoarthritis or rheumatoid arthritis, and should be used as part of a clinically supervised musculoskeletal management plan when symptoms are persistent or progressive.
Specifications
| Manufacturer | Science Research Wellness Limited (SRW Laboratories), Auckland, New Zealand |
|---|---|
| Format / Pack | 60 vegetarian capsules (HPMC); 30-day supply at 2 capsules/day |
| Active Ingredients (per 2 capsules) | NEM® eggshell membrane 500 mg; 5-LOXIN® Boswellia serrata gum-resin extract 100 mg (standardised ≥30% AKBA); Palmitoylethanolamide (PEA) 300 mg |
| Excipients | Microcrystalline cellulose, hypromellose (capsule), magnesium stearate (vegetable source), silicon dioxide |
| Allergen Profile | Contains egg (NEM® is derived from chicken eggshell membrane). Free of gluten, dairy, soy, GMO, and added sugar. |
| Manufacturing Standard | Manufactured under cGMP in a TGA-licensed facility (Australia/NZ supply chain); ISO 9001 quality management at the contract manufacturer |
| Quality References | NEM® clinical evidence summarised in Ruff et al., Clin Interv Aging 2009;4:235–240. 5-LOXIN® AKBA standardisation per Sengupta et al., Arthritis Res Ther 2008. |
| Regulatory Status (Singapore) | Notified as a health supplement under the Singapore Health Sciences Authority (HSA) Health Products Act framework. TGA-listed in Australia under AUST L (parent listing). |
| Storage | Store below 25°C in a dry place; keep out of reach of children |
Clinical Indications & Use Cases
- Adults ≥40 with age-related joint stiffness, reduced morning mobility, or perceived loss of joint flexibility
- Recreational and masters-level athletes managing repetitive load on knees, shoulders, or lumbar facet joints
- Office workers with sedentary load patterns presenting with cervical and lumbar joint stiffness
- Adjunct nutritional support alongside physiotherapy and structured strength/mobility programmes
- Adults wishing to support normal MMP-3 (matrix metalloproteinase-3) regulation as part of a longevity-focused supplement stack
- Individuals seeking a glucosamine-free, shellfish-free joint formulation
Frequently Asked Questions
Q: How does NEM® eggshell membrane differ from glucosamine/chondroitin?
A: Glucosamine and chondroitin are isolated single-molecule actives, typically derived from shellfish or bovine cartilage. NEM® is a whole-matrix eggshell membrane delivering naturally complexed type-I collagen, glycosaminoglycans (chondroitin, hyaluronic acid, dermatan sulfate), and structural peptides at a 500 mg/day dose. Randomised data (Ruff 2009; Brunello 2017) report symptomatic benefit at 7–30 days, an earlier onset than the 8–12 weeks typical for glucosamine sulfate.
Q: What is the role of 5-LOXIN® (AKBA)?
A: 5-LOXIN® is standardised to ≥30% acetyl-11-keto-β-boswellic acid (AKBA), a selective inhibitor of 5-lipoxygenase. By moderating leukotriene-mediated inflammatory signalling, AKBA supports normal MMP-3 activity and cartilage extracellular-matrix preservation (Sengupta et al., Arthritis Res Ther 2008).
Q: Is Palmitoylethanolamide (PEA) compatible with prescription analgesics?
A: PEA is an endogenous N-acylethanolamine with no documented pharmacokinetic interaction with NSAIDs, paracetamol, or weak opioids. It should not, however, replace prescribed analgesia. Patients on chronic pain regimens should discuss combined use with the prescribing physician, particularly where neuropathic pain protocols are in place.
Q: How is this supplement regulated for sale in Singapore?
A: In Singapore, the Health Sciences Authority (HSA) classifies oral joint-health supplements under the Health Products Act as health supplements rather than therapeutic products. They are exempt from pre-market HSA registration but must comply with prohibited-substance lists, labelling requirements, and post-market surveillance. EMIS+ retains supplier Certificates of Analysis and lot traceability records.
Q: Are there contraindications I should be aware of?
A: The product contains egg-derived NEM®; it is contraindicated in egg allergy. PEA and Boswellia at supplemental doses are generally well tolerated; however, the formulation is not recommended during pregnancy or lactation in the absence of clinician advice. Discontinue and seek medical review if joint symptoms persist beyond 12 weeks of consistent use.
分享
